Advancing Medical reviews with AI
June 27th 2024AI can be applied to patient data in real time, allowing medical reviewer teams to actively monitor patient safety, with the AI alerting medical review teams to identify potential adverse events (AEs), data anomalies, critical issues for patients on treatment, and more.
Physician Targeting Using Real-Time Data
June 20th 2024By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. Alerts, powered by PurpleLab translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.
The Shift Toward Precision Medicine Requires Claims Data Insights
June 20th 2024Healthcare today is evolving into precision medicine, or what the FDA refers to as personalized medicine. To stay competitive in the constantly shifting healthcare landscape, organizations across the healthcare ecosystem must embrace this targeted approach and leverage the tools needed to make safe decisions for their patients or populations. By unlocking insights provided from advanced claims data, precision medicine can assist clinicians, thereby reducing their educated guesses, improving patient outcomes, and making more informed decisions.
Accelerating the Use of RWD for Oncology Clinical Trial Planning
June 20th 2024As medical facilities become more equipped to handle different telemedicine platforms and procedures, more clinical trials are back up and running. This also means more electronic data is being generated than ever. This Ebook will explain how to reach patients and facilities, especially in this decentralized clinical trial format.
Emerging Biosimilars and the Importance of Identifying Experienced Providers
June 20th 2024Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
The Nuances of Patient Selection: Why Some Trials Need Eligibility Adjudication
June 18th 2024Patient selection can be a nuanced process in clinical trials, particularly those involving therapeutic areas with more complex or subjective inclusion/exclusion criteria. Determining patient eligibility may often depend on factors that require clinical expertise in such areas as disease progression, comorbidities, genetic mutations, and disease severity. Discover the role eligibility adjudication committees play in ensuring trial success.
The Top 5 Benefits: Outsourcing Expert Committee Management to an Independent Provider
June 18th 2024EACs/CECs evaluate potential adverse events, participants’ safety, whether a patient meets complex eligibility criteria, and much more. Thus, the need to select the right EAC vendor is critical – selecting the wrong partner risks time, money, and success. With so many EAC vendors, it can be challenging to find the ideal partner. Fortunately, WCG has outlined the top five benefits of utilizing an independent EAC.
Understanding Endpoint & Safety Review
June 18th 2024No clinical trial is successful without careful attention not only to how endpoints are crafted, but how they are reviewed and applied. This article will describe the use of Imaging Core Labs and Endpoint Adjudication Committees (EACs) to increase the quality and accuracy of clinical trial data. Additionally, it will clarify the differences between these critical endpoint review methods and other forms of safety review.
5 reasons why the right people aren’t joining your trials
May 30th 2024Determining the most effective locations and formats to get your clinical trial in front of willing, eligible participants can seem like a daunting task.. What is the most efficient way to introduce more targeted recruitment approaches?
Mobile Visits in Decentralized Clinical Trials: The Past, Present and Future
May 7th 2024In March 2024, the US FDA issued its guidance, “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” outlining the agency’s objectives for protecting public health as artificial intelligence (AI) and other technologies become more prevalent in healthcare.
Digital Biomarkers Solution shows pathway to reduced clinical trial sample sizes, shorter durations
April 5th 2024Digital biomarkers provide a pathway to the future where clinical trial sponsors can potentially benefit from reduced trial duration and sample size. Learn more about these benefits from a simulated study.
EHR-to-EDC Technology: A Guide to Modern Data Acquisition in Oncology Clinical Trials
December 20th 2023Inside this eBook, readers can expect to learn how to effectively navigate the various challenges associated with clinical trial data collection and reporting in the age of digitalization and at a time in which site staff are experiencing turnover and seeking more efficiency.